1 / 14

100K GFP-positive

A. B. Mir93-Sensor-GFP. C. D. 100K GFP-negative. 100K GFP-positive. 10K GFP-negative. 10K GFP-positive. 1K GFP-negative. 1K GFP-positive. 1K Unseparated. 100K Unseparated. Tumor generated from GFP-positive cells. Tumor generated from GFP-negative cells. DAPI. DAPI. DAPI.

barth
Télécharger la présentation

100K GFP-positive

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A B Mir93-Sensor-GFP C D 100K GFP-negative 100K GFP-positive 10K GFP-negative 10K GFP-positive 1K GFP-negative 1K GFP-positive 1K Unseparated 100K Unseparated Tumor generated from GFP-positive cells Tumor generated from GFP-negative cells DAPI DAPI DAPI GFP GFP+ GFP- GFP GFP Figure 1 (SUM159)

  2. B A Lung Spine Brain DAPI Annexin V-APC CONTROL DOX 0.13% 4.47% 0.14% 2.09% 0.53% 8.86% 6.78% 51.9% 56.4% 39% 24.2% 66.4% 12.5% 18.9% 52.1% 45.7% DOCETAXEL E C D DOX + DOCETAXEL F H Treatment Start Treatment Stop Treatment Start Treatment Start G Treatment Stop Treatment Start Treatment Start Figure S1 (HCC1954 In vitro, in vivo)

  3. Lung Leg DAPI Annexin V-APC Treatment start Heart Kidney B A CONTROL Pan-ck Pan-ck Pan-ck Pan-ck Treatment stop Treatment start Treatment start DOX Pan-ck Pan-ck Pan-ck Pan-ck DOCETAXEL Pan-ck Pan-ck Pan-ck Pan-ck E D C DOX + DOCETAXEL 0.09% 1.12% 0.06% 1.61% 0.4% 42.8% 0.65% 44.65% Pan-ck Pan-ck Pan-ck Pan-ck 92% 6.83% 90.8% 7.5% 27.4% 29.4% 30.1% 24.6% Treatment Start F H Treatment start Treatment stop G Figure 2 (SUM159)

  4. A B Treatment Start Treatment Start Figure S2 (MC1, UM2)

  5. A B D SUM159-Neg-DsRed SUM159 Non-infection SUM159-mirZip93-DsRed C SUM159-mir93 control SUM159-mir93 DOX Figure S3 (SUM159)

  6. A D B E C Treatment start Figure 3 (MCF7)

  7. Non-CD24-CD44+ CD24-CD44+ ALDH- ALDH+ ALDH- ALDH+ Figure S4

  8. TET-inducible mir93 lentivirus infected SUM159 (SUM159-mir93) A FACS ALDH- cells ALDH+ cells in suspension culture +/- Tetracycline (10 hrs) CTRL DOX CTRL DOX RNA isolation Affymetrix array CTRL DOX CTRL DOX RMA method 352 probesets downregulated with at least 2-fold changes 2110 probesets downregulated with at least 2-fold changes Compare to the predicted targets from TargetScan 12 Overlapped targets (0 stem cell genes) 127 Overlapped targets (>24 stem cell genes) B Figure 4 (SUM159)

  9. Table S1

  10. Figure S5 (HCC1954)

  11. B A CTRL 0.86% G0/G1: 64% S/G2/M: 34% DOX 47.31% 57.47% 48.58% 39.08% G0/G1: 42% S/G2/M: 53% SUM159-mir93 Figure 5

  12. CTRL DOX G0/G1: 31% S/G2/M: 68% G0/G1: 47% S/G2/M: 48% HCC1954-mir93 G0/G1: 53% S/G2/M: 42% G0/G1: 47% S/G2/M: 49% MCF7-mir93 Figure S6

  13. Ki67 MCM7 DAPI Merge TOTAL ALDH+ ALDH- Figure S7

  14. stem cell Mir93 - Mcm7 - Proliferating early progenitors Myc Self-renewal Differentiated cells Mir93 + Mcm7 + Quiescent stem cell pool SUM159 Mir93 - Mcm7 - ALDH+ Mcm7 Mir93 Mcm7 HCC1954 mir93 E2F1 Differentiation Cell proliferation CSC MCF7 ALDH- Figure 6

More Related